IFNB1 and COVID-19: Regarding the clinical use of transcriptomic biomarkers in COVID-19, only nCounter technology was able to reliably detect IFNB1 as well as other low-abundance transcripts (MASP2 and THY1) when compared to single-cell RNA sequencing (RNA-seq) analysis of both nasal mucosa23 and blood24 (data not shown).